Abstract
Fosfomycin is a potential option for vancomycin-resistant enterococcus (VRE) infections despite limited in vitro and clinical data. In this study, 32 VRE isolates from renal transplant patients with urinary stent infections were susceptible to fosfomycin, daptomycin, and linezolid and resistant to amoxicillin, minocycline, and nitrofurantoin based on their MIC(50)s and MIC(90)s. Fosfomycin was bacteriostatic at 0.5 to 16× the MIC (32 to 2,048 μg/ml); synergy occurred when fosfomycin was combined with daptomycin (2.8 to 3.9 log(10) CFU/ml kill; P < 0.001) or amoxicillin (2.6 to 3.4; P < 0.05). These combinations may be potent options to treat VRE urinary infections pending investigation of clinical efficacy.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acetamides / pharmacology*
-
Amoxicillin / pharmacology*
-
Anti-Bacterial Agents / pharmacology*
-
Daptomycin / pharmacology*
-
Drug Synergism
-
Enterococcus faecium / drug effects*
-
Enterococcus faecium / growth & development
-
Enterococcus faecium / isolation & purification
-
Fosfomycin / pharmacology*
-
Gram-Positive Bacterial Infections / drug therapy
-
Gram-Positive Bacterial Infections / microbiology
-
Humans
-
Kidney Transplantation
-
Linezolid
-
Microbial Sensitivity Tests
-
Oxazolidinones / pharmacology*
-
Stents / microbiology
-
Urinary Tract / drug effects
-
Urinary Tract / microbiology
-
Urinary Tract Infections / drug therapy
-
Urinary Tract Infections / microbiology
-
Vancomycin / pharmacology
-
Vancomycin Resistance
Substances
-
Acetamides
-
Anti-Bacterial Agents
-
Oxazolidinones
-
Fosfomycin
-
Vancomycin
-
Amoxicillin
-
Linezolid
-
Daptomycin